---
title: "Merck's first HIF-2α inhibitor phase III study results for renal cell carcinoma are out"
type: "News"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/news/263385166.md"
description: "Merck announced that its HIF-2α inhibitor belzutifan, in combination with lenvatinib, achieved the primary endpoint in the Phase III LITESPARK-011 trial for the treatment of advanced renal cell carcinoma, showing significant improvements in progression-free survival (PFS) and objective response rate (ORR). Renal cell carcinoma is the most common type of kidney cancer, with approximately 435,000 new cases diagnosed globally in 2022"
datetime: "2025-10-29T23:04:02.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/263385166.md)
  - [en](https://longbridge.com/en/news/263385166.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/263385166.md)
---

> 支持的语言: [English](https://longbridge.com/en/news/263385166.md) | [繁體中文](https://longbridge.com/zh-HK/news/263385166.md)


# Merck's first HIF-2α inhibitor phase III study results for renal cell carcinoma are out

According to Zhitong Finance APP, on October 28, Merck (MRK.US) announced two pieces of news: 1) The Phase III LITESPARK-011 trial evaluating the dual oral therapy Welireg (belzutifan) in combination with lenvatinib for the treatment of advanced renal cell carcinoma patients who have experienced disease progression after prior anti-PD-1/L1 therapy has achieved one of its primary endpoints of progression-free survival (PFS). Belzutifan is Merck's first-in-class oral hypoxia-inducible factor-2α (HIF-2α) inhibitor.

![1761778837622.png](https://imageproxy.pbkrs.com/https://img.zhitongcaijing.com/image/20251030/1761778846921296.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg)

In the pre-specified interim analysis, the combination of belzutifan and lenvatinib showed statistically significant and clinically meaningful improvement in PFS compared to cabozantinib. This combination therapy also demonstrated statistically significant improvement in the trial's key secondary endpoint of objective response rate (ORR) compared to cabozantinib.

Renal cell carcinoma (RCC) is the most common type of kidney cancer, accounting for approximately nine-tenths of kidney cancer diagnoses. In 2022, there were approximately 435,000 new cases of kidney cancer diagnosed globally, with about 156,000 deaths from the disease. The incidence of RCC in men is about twice that of women. Most cases of renal cell carcinoma are incidentally discovered during imaging examinations for other abdominal diseases. Approximately 30% of kidney cancer patients are diagnosed at an advanced stage

### 相关股票

- [Merck (MRK.US)](https://longbridge.com/zh-CN/quote/MRK.US.md)

## 相关资讯与研究

- [Merck Says EU Approves Keytruda Combination Regimen for Platinum-Resistant Ovarian Cancer](https://longbridge.com/zh-CN/news/281517399.md)
- [Texas Pacific Land Corporation $TPL Shares Bought by JB Capital LLC](https://longbridge.com/zh-CN/news/281707609.md)
- [Sprott Files 6-K and Sets Virtual AGM for May 6, 2026](https://longbridge.com/zh-CN/news/281537158.md)
- [C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors Invests $1.43 Million in McKesson Corporation $MCK](https://longbridge.com/zh-CN/news/281705093.md)
- [Hershey Stock (HSY) Looks Sweeter After Company Promises Return to Classic Reese's](https://longbridge.com/zh-CN/news/281415413.md)